AlphAIalphai — Financial news for AI agents
StockOTC · US · USDHealthcare · Biotechnology

$TTIPF

Thiogenesis Therapeutics, Corp.

Price · $TTIPFvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $TTIPF in the last 7 days.

Insider · 30dAll trades →

No SEC Form 4 filings for $TTIPF in the last 30 days.

See all $TTIPF insider activity →
Top stories · $TTIPFMore →
SEP 3·finanznachrichten.deLow

Thiogenesis Therapeutics, Corp.: Thiogenesis Engages Brisco Capital for Investor Relations

Thiogenesis Therapeutics (TSXV: TTI, OTCQB: TTIPF) hired Brisco Capital for investor relations, paying $6,000 monthly plus stock options. The company plans to amend its equity incentive plan, increasing reserved shares from 9,099,095 to 13,995,931, subject to shareholder approval. Thiogenesis develops sulfur-based therapeutics for rare diseases, with lead candidate TTI-0102 in clinical development.

See more news on $TTIPF →

TTIPF sentiment & insider activity

What's driving TTIPF

  • Thiogenesis Therapeutics (TSXV: TTI, OTCQB: TTIPF) hired Brisco Capital for investor relations, paying $6,000 monthly plus stock options. The company plans to amend its equity incentive plan, increasing reserved shares from 9,099,095 to 13,995,931, subject to shareholder approval. Thiogenesis develops sulfur-based therapeutics for rare diseases, with lead candidate TTI-0102 in clinical development.

    finanznachrichten.de · Sep 3, 2026

alphai scores every news story that mentions TTIPF with an AI model for sentiment and relevance, and aggregates insider trades from Thiogenesis Therapeutics, Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $TTIPF

Score
SEP 3Lowfinanznachrichten.de

Thiogenesis Therapeutics, Corp.: Thiogenesis Engages Brisco Capital for Investor Relations

Thiogenesis Therapeutics (TSXV: TTI, OTCQB: TTIPF) hired Brisco Capital for investor relations, paying $6,000 monthly plus stock options. The company plans to amend its equity incentive plan, increasing reserved shares from 9,099,095 to 13,995,931, subject to shareholder approval. Thiogenesis develops sulfur-based therapeutics for rare diseases, with lead candidate TTI-0102 in clinical development.

2 min read

Related tickers

More in Biotechnology